Association for Immunotherapy of Cancer: Cancer Immunotherapy - 2nd Annual Meeting

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes

R Weth, M Biburger and W Wels

Cancer Cell International 2004 4(Suppl 1):S1

Published on: 1 July 2004

Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation

A Hombach, C Heuser and H Abken

Cancer Cell International 2004 4(Suppl 1):S2

Published on: 1 July 2004

Tolerability and efficacy of the trifunctional antibody removab^® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study

P Wimberger, A Burges, V Gorbounova, H Sommer, B Schmalfeldt, J Pfisterer, M Lichinitser, A Makhson, M Ströhlein, W Eiermann, M Biakhov, V Moiseenko, A du Bois and R Kimmig

Cancer Cell International 2004 4(Suppl 1):S3

Published on: 1 July 2004

HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy

Y Wachter, J Brünke, S Schuster, K Barbin, M Peipp, T Valerius, M Gramatzki, G Fey and R Repp

Cancer Cell International 2004 4(Suppl 1):S4

Published on: 1 July 2004

Increased frequency of CTLA4⁺ TGFβ⁺ CD4⁺ CD25⁺ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma

M Beyer, M Kochanek, M von Bergwelt-Baildon, A Popov, J Wolf and JL Schultze

Cancer Cell International 2004 4(Suppl 1):S5

Published on: 1 July 2004

MMP-7 inhibits CTL – tumor cell interaction

S Gregor, V Alla, J Kuball, M Theobald, PR Galle, D Strand and S Strand

Cancer Cell International 2004 4(Suppl 1):S6

Published on: 1 July 2004

Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM

C Uherek, T Müller, T Tonn, B Uherek, H-G Klingemann and WS Wels

Cancer Cell International 2004 4(Suppl 1):S7

Published on: 1 July 2004

Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus

E Scandella, P Krebs, B Odermatt and B Ludewig

Cancer Cell International 2004 4(Suppl 1):S8

Published on: 1 July 2004

High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma

N Meidenbauer, A Zippelius, MJ Pittet, M Laumer, S Vogl, J Heymann, M Rehli, B Seliger, S Schwarz, F-A Le Gal, PY Dietrich, R Andreesen, P Romero and A Mackensen

Cancer Cell International 2004 4(Suppl 1):S9

Published on: 1 July 2004

Adoptive T cell therapy using antigen-specific CD8⁺ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study

N Meidenbauer, S Vogl, M Laumer, J Heymann, R Andreesen and A Mackensen

Cancer Cell International 2004 4(Suppl 1):S10

Published on: 1 July 2004

Large scale in vitro expansion of polyclonal human CD4⁺CD25^high regulatory T cells

P Hoffmann, R Eder, LA Kunz-Schughart, R Andreesen and M Edinger

Cancer Cell International 2004 4(Suppl 1):S11

Published on: 1 July 2004

Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens

J Neudorfer, B Schmidt, K Huster, M Schiemann, T Schmidt, H Wagner, C Peschel, DH Busch and H Bernhard

Cancer Cell International 2004 4(Suppl 1):S12

Published on: 1 July 2004

Therapeutic efficacy of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell clones in renal cell carcinoma

N Oehlrich, M Linnebacher, S Stevanovic and M Zoeller

Cancer Cell International 2004 4(Suppl 1):S13

Published on: 1 July 2004

The role of glycosylation as a modulator for signalling strength in T cells

B Hauptrock, J Kuball, R-H Voss, M Brkic, C Huber and M Theobald

Cancer Cell International 2004 4(Suppl 1):S14

Published on: 1 July 2004

Migration of dendritic cells to regional lymph nodes in a vaccination trial

A Riccobon, R Ridolfi, R Galassi, M Petrini, M Stefanelli, L Fiammenghi, G Giorgetti, A Moretti, L Ridolfi and G Fiorentini

Cancer Cell International 2004 4(Suppl 1):S15

Published on: 1 July 2004

Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer

AK Kaskel, R Zeiser, R Jochim, W Schultze-Seemann, CF Waller and H Veelken

Cancer Cell International 2004 4(Suppl 1):S16

Published on: 1 July 2004

Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML

A Letsch, C Scheibenbogen, AM Asemissen, V Mailänder, E Thiel and U Keilholz

Cancer Cell International 2004 4(Suppl 1):S17

Published on: 1 July 2004

LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers

A Bender, J Karbach, A Neumann, M Biskamp, D Jäger, S Gnjatic, E Hoffman, LJ Old, A Knuth and E Jäger

Cancer Cell International 2004 4(Suppl 1):S18

Published on: 1 July 2004

Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing murine host

M Zöller

Cancer Cell International 2004 4(Suppl 1):S19

Published on: 1 July 2004

Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation™)

K Hellendoorn, T Jones, J Watkins, M Baker, A Hamilton and F Carr

Cancer Cell International 2004 4(Suppl 1):S20

Published on: 1 July 2004